Alkem Laboratories, a Rs.3,800 crore plus pharma giant established in 1973, is entering capital market on December 8, 2015 with an initial public offering of upto 1,28,53,442 equity shares of Rs.2 each offered by its shareholders. The price band is fixed in the range of Rs.1020-1050 through book building process. The equity shares offered through Red Herring prospectus are proposed to be listed on BSE and NSE. The global co-ordinators and book running lead managers are Nomura Financial Advisory and Securities (I) Pvt Ltd, Axis Capital Ltd, J. P. Morgan India Pvt Ltd and Edelweiss Financial Services Ltd. Link Intime India Pvt Ltd will be registrar to the offer. The issue will close on December 10, 2015.

The company's consolidated net sales for the year ended March 2015 increased to Rs.3,789 crore from Rs.3,126 crore in the previous year. It earned a net profit moved up to Rs.463 crore from Rs.435 crore. As against the equity capital of Rs.23.91 crore, its reserves & surplus stood at Rs.2,971 crore. The company is engaged in branded generics, generic drugs, APIs and nutraceuticals and marketing its products in over 55 countries. For the fiscal year 2015, its domestic and international operations accounted for 74.7 per cent and 25.3 per cent respectively of its total revenues. The company is focusing on US through its marketing subsidiary, Ascend Laboratories LLC.


Alkem is mainly focusing on anti-infectives, gastro-intestinal, pain and analgesics, and vitamins, minerals and nutrients. These therapeutic areas accounted for 80.7 per cent of its total sales in the domestic market.

For the first half ended September 2015, Alkem's consolidated net sales increased to Rs.2,570 crore from Rs.1,889 crore in the corresponding period of last year. Its net profit increased to Rs.431.29 crore from Rs.171.19 crore.